Clinical trial
ARQ 501 in Combination With Docetaxel in Patients With Cancer
NCT00099190 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Industry · Completed
Key facts
| NCT number | NCT00099190 |
|---|---|
| Title | ARQ 501 in Combination With Docetaxel in Patients With Cancer |
| Official title | A Phase Ib Safety and Pharmacokinetic Study of ARQ 501 in Combination With Docetaxol in Adult Patients With Locally Advanced or Metastatic Carcinoma |
| Lead sponsor | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma |
| Intervention type | Drug |
| Interventions | ARQ 501 |
| Enrollment | 50 |
| Start date | Dec 1, 2004 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Dec 10, 2004 |
| Last update posted | Apr 28, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: